查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1732130

全球感染疾病物市場規模（按藥物類型、適應症、分銷管道、區域範圍和預測）

Global Anti Infective Drugs Market Size By Drug Type (Antibiotics, Antivirals), By Indication (HIV, Pneumonia, Respiratory Infections), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

感染疾病物市場規模及預測

2024 年感染疾病物市場規模價值為 1,387.7 億美元，預計到 2032 年將達到 2,058.1 億美元，2026 年至 2032 年的複合年成長率為 5.05%。

推動市場擴張的關鍵因素是流感的日益普及。作為一種傳染性病毒，流感可引起輕度至中度症狀，以及嚴重的併發症，甚至導致死亡。本報告對全球感染疾病市場進行了全面的評估，涵蓋了各個細分市場的分析，以及對市場產生重大影響的趨勢和因素。

定義全球感染疾病物市場

感染疾病是世界衛生組織（WHO）認定的全球主要健康負擔之一。感染疾病是由多種病原體引起的致命疾病，包括細菌、真菌和病毒感染。感染疾病是治療多種病原體感染疾病的常用治療方法。抗感染藥物用於消滅感染疾病，或阻止其複製並透過釋放各種毒素感染宿主。

引起感染疾病的微生物包括細菌、病毒、真菌、病毒和微小寄生蟲。感染疾病根據其致病微生物的類型以及患者疾病的體徵和症狀進行分類。感染疾病是當今全球面臨的最重大健康問題之一。感染疾病是由許多病原體引起的致命疾病，包括細菌感染、真菌感染和病毒感染。感染疾病傳播迅速，感染疾病物用於治療各種微生物，包括真菌、細菌、病毒和其他病原體。

感染疾病是常用於治療各種原因引起的感染疾病的治療方法。感染疾病透過多種途徑發揮作用，例如抑制DNA生成或破壞細胞成分以阻止感染擴散。抗感染藥感染疾病市場由生產用於治療微生物疾病的品牌或非專利感染疾病的營業單位（組織、獨資企業、夥伴關係）以及相關產品和服務的實體組成。

全球感染疾病物市場概覽

由於人類免疫力缺乏病毒（HIV）破壞免疫系統，人類越來越容易感染疾病。如果不及時治療，HIV 會導致後天免疫力缺乏症候群（AIDS）。根據聯合國愛滋病規劃署（UNAIDS）的數據，光是 2020 年，全球就有約 150 萬人感染 HIV。 HIV 會傷害並殺死 CD4 細胞，即白血球。這會削弱人體抵抗疾病的能力。抗病毒藥物可阻止病毒繁殖，降低體內 HIV 水平並重新激活免疫系統的細胞生成。推動市場擴張的另一個關鍵因素是流感疫情日益嚴重的因素。流感是一種傳染性病毒，可引起輕度至中度症狀以及嚴重併發症，包括死亡。

美國疾病管制與預防中心 (CDC) 報告稱，2018-2019 年流感導致 3550 萬人患病、490,600 人住院和 34,200 人死亡，這推動了抗感染藥感染疾病行業的擴張。預計感染疾病市場將受益於藥物研發方法的最新進展，例如骨髓和器官晶片 (OOC) 技術。 OOC 是精心建構的生物識別系統，用於複製器官系統的運動、行為和生理反應。標靶識別、檢驗和篩檢是使用 OOC 和幹細胞技術的臨床試驗程序的範例。這些技術正在降低藥物開發成本，並提供對藥物在人體中的療效和安全性的可靠預測。

然而，高昂的研發成本和醫療機構資源的匱乏可能會限制市場發展。然而，世界衛生組織 (WHO) 預測，到 2030 年，六分之一的人將超過 60 歲，到 2050 年，全球 60 歲以上人口將加倍，達到 21 億。預計 2020 年至 2050 年間 80 歲以上人口將成長兩倍，達 4.26 億。與老齡化相關的免疫系統劣化會降低人體抵抗疾病和回應疫苗的能力。免疫系統區分自身和外來病原體的能力會下降。保留先前遇到的抗原記憶的 T 細胞對新抗原的反應性會降低。合併症的增加和免疫系統活動的減弱使人們更容易感染疾病，這推動了市場成長。

目錄

第1章全球感染疾病物市場簡介

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第 2 章 已驗證的市場研究調查方法

  • 資料探勘
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 業界專家的重要見解
  • 資料來源

第3章執行摘要

  • 市場概覽
  • 生態測繪
  • 絕對的商機
  • 市場吸引力
  • 全球感染疾病物市場區域分析（複合年成長率%）
  • 全球感染疾病物市場（按藥物類型）
  • 全球感染疾病物市場（依適應症分類）
  • 全球感染疾病物市場（按分銷管道）
  • 未來市場機會
  • 世界市場結構
  • 產品生命線

第4章感染疾病物的全球市場展望

  • 全球感染疾病物的演變
  • 驅動程式
    • 促進要素1
    • 促進要素2
  • 限制因素
    • 約束因素 1
    • 約束因素 2
  • 機會
    • 機會1
    • 機會2
  • 波特五力模型
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

全球感染疾病物市場（按藥物類型）

  • 概述
  • 抗生素
  • 抗病毒藥物
  • 抗真菌藥物

5. 全球感染疾病物市場（依適應症分類）

  • 概述
  • HIV
  • 肺炎
  • 呼吸道感染疾病
  • 結核
  • 其他

6. 全球感染疾病物市場按分銷管道分類

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

7. 全球感染疾病物市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第8章全球感染疾病物市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要進展
  • 公司地理分佈
  • 公司在各行業的足跡
  • ACE矩陣

第9章 公司簡介

  • Novartis AG
  • Merck & Co., Inc
  • Alcon Pharmaceuticals Ltd
  • Quest Diagnostics Inc.
  • AstraZeneca Plc
  • Anofi SA
  • GSK
  • Gilead Sciences
  • Novartis AG
  • Cipla

第10章 已驗證的市場情報

  • 關於已驗證的市場情報
  • 動態資料視覺化
Product Code: 30945

Anti Infective Drugs Market Size And Forecast

Anti Infective Drugs Market size was valued at USD 138.77 Billion in 2024 and is projected to reach USD 205.81 Billion by 2032, growing at a CAGR of 5.05% from 2026 to 2032

An important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death. The Global Anti Infective Drugs Market report provides a holistic evaluation of the market. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Anti Infective Drugs Market Definition

One of the major global health burdens recognised by the World Health Organisation (WHO) is infectious illnesses. It is a potentially lethal illness brought on by a number of pathogens, such as bacterial, fungal, and viral infections. Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs are used to eliminate infection-causing organisms or stop them from replicating or infecting the host by releasing a variety of toxins.

Microorganisms that cause infections include bacteria, viruses, fungi, viruses, and microparasites. Infections are categorised according to the type of organism that causes them as well as the patient's signs and symptoms of illness. One of the most significant health issues facing the entire globe today is infectious diseases. It is a potentially lethal illness brought on by a number of pathogens, including bacterial, fungal, and viral infections. Infectious diseases spread swiftly, and anti-infective drugs are used to treat a wide variety of microbiological species, including fungi, bacteria, viruses, and other pathogens.

Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs function in several ways, such as by blocking DNA production and/or by destroying the cellular component to stop the infection from spreading. The Anti Infective Drugs Market is populated by entities (organisations, sole traders, and partnerships) that produce branded or generic anti-infective pharmaceuticals to treat microbial illnesses as well as related products and services.

Global Anti Infective Drugs Market Overview

Humans are increasingly becoming susceptible to infections as a result of the human immunodeficiency virus (HIV), which damages the immune system. If HIV is not treated in a timely manner, Acquired Immunodeficiency Syndrome (AIDS) may manifest. Around 1.5 million people worldwide contracted HIV in 2020 alone, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV causes harm to or kills CD4 cells, often known as white blood cells. This interferes with the body's ability to fight disease. Antiviral medications prevent the virus from multiplying, lowering the body's level of HIV and reactivating the immune system's cell production. Another important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death.

The expansion of the anti-infective drugs industry was boosted by the 35.5 million people who contracted influenza in 2018-2019, the Centres for Disease Control and Prevention (CDC) reports, which led to 490,600 hospitalisations and 34,200 fatalities. The Anti Infective Drugs Market is expected to benefit from recent advances in drug discovery methods, such as bone marrow and organ-on-chip (OOC) technology. OOCs are biometric systems that have been meticulously built to replicate the motions, movements, and physiological responses of organ systems. Target identification, validation, and screening are examples of clinical trial procedures that use OOC and stem cell technologies. These technologies are reducing the expenses associated with drug development and provide reliable predictions of medicinal efficacy and human safety.

Market expansion, however, can be constrained by high research and development costs as well as a lack of resources in healthcare facilities. However, The World Health Organisation (WHO) predicts that by 2030, one in every six people will be 60 years of age or older and that by 2050, the number of people in the world who are 60 years of age or older will have doubled (to 2.1 billion). The number of people 80 and older is expected to treble between 2020 and 2050, reaching 426 million. Age-related immune system deterioration renders the body's capacity to fight disease and respond to immunisations less effective. The immune system becomes less adept at telling self-agents apart from alien ones. T cells that retain memories of previously met antigens react less quickly to novel antigens. Due to an increase in comorbid disorders and a decline in immune system activity, people are more susceptible to infections, which is what is causing the market to grow.

Global Anti Infective Drugs Market Segmentation Analysis

The Global Anti Infective Drugs Market is segmented on the basis of Drug Type, Indication, Distribution Channel, And Geography.

Anti Infective Drugs Market, By Drug Type

  • Antibiotics
  • Antivirals
  • Antifungals

Based on Drug Type, the market is segmented into Antibiotics, Antivirals, and Antifungals. Anti-infective medications known as antibiotics are used to treat bacterial infections. They function by either eradicating the germs or preventing them from proliferating, allowing the body's immune system to successfully combat the infection. A variety of bacterial illnesses, including those of the respiratory system, skin, urinary tract, and ears, are frequently treated with antibiotics. They come in a variety of forms, including tablets, capsules, injections, creams, and ointments.

  • A class of anti-infective medication known as antiviral is used to treat viral infections. They function by concentrating on the virus and halting its reproduction and spread throughout the body. Virus diseases like the flu, herpes, HIV/AIDS, hepatitis B and C, and other viral infections are frequently treated with antivirals. Depending on the infection type being treated, they can be given orally, topically, or intravenously.

Anti Infective Drugs Market, By Indication

  • HIV
  • Pneumonia
  • Respiratory Infections
  • Tuberculosis
  • Others

Based on Indication, the market is segmented into HIV, Pneumonia, Respiratory Infections, Tuberculosis, and Others. Pneumonia is an infection of the lungs that can be brought on by bacteria, viruses, fungi, or other pathogens. Anti-infective medications are used to treat pneumonia. Depending on the underlying cause of the infection, the anti-infective medication used to treat pneumonia is chosen. The initial line of therapy for bacterial pneumonia is antibiotics. They function by eliminating infection-causing germs and lowering lung inflammation. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are a few of the typical antibiotics used to treat bacterial pneumonia.

  • Antibiotics are frequently used as the first line of treatment for bacterial respiratory infections like streptococcal pharyngitis (strep throat), bacterial sinusitis, and bacterial pneumonia. The particular antibiotic administered will depend on the kind of bacteria that is infected and how susceptible it is to various medications. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are typical antibiotics used to treat bacterial respiratory infections.

Anti Infective Drugs Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Anti-infective medication is primarily distributed via hospital pharmacies. These pharmacies are in charge of obtaining, holding, dispensing, and controlling the stock of medications used to treat infections in the hospital context. Given the high prevalence of infectious disorders among hospitalised patients, anti-infective treatments are among the most often prescribed ones in hospitals.

  • To ensure proper selection, dose, and administration of anti-infective medications, hospital pharmacies often collaborate closely with doctors, including infectious disease specialists and other healthcare professionals. In addition, they are in charge of keeping an eye on and handling any potential negative drug effects, interactions, and problems with drug resistance.

Anti Infective Drugs Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of The World
  • On the basis of Geography, the Global Anti Infective Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The biggest market share was held by North America in 2022. In recent years, a number of reasons have contributed to an increase in the need for anti-infective medications in North America. The rising incidence of infectious diseases, notably bacterial and viral infections, in the area is one of the major contributors to this trend.
  • The need for anti-infective medications has also been influenced by the ageing population and the rise in chronic illnesses including diabetes, cancer, and HIV/AIDS. The expanding prevalence of infections that are resistant to treatment is another factor influencing the increased demand for anti-infective medications in North America. To treat these infections, new and improved antibiotics and antiviral medications are now required.

Key Players

The "Global Anti Infective Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novartis AG, Merck & Co., Inc., Alcon Pharmaceuticals Ltd., Quest Diagnostics Inc., AstraZeneca Plc., Anofi SA, GSK, Gilead Sciences, Novartis AG, and Cipla.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

  • In August 2021, Pharmaceutical business Xellia Pharmaceuticals, which specialises in anti-infective medications, increased its Ohio production capacity. They distributed the first anti-infectives produced at the facility to US hospitals.
  • In April 2021, Pfizer, a large global pharmaceutical and biotechnology company, acquired Amplyx Pharmaceuticals, Inc., a business that creates treatments for crippling and fatal illnesses and added Fosmanogepix, a novel antifungal Phase 2 candidate (APX001), to its anti-infectives portfolio. Pfizer now owns Amplyx's early-stage therapeutic portfolio, which includes antiviral (MAU868) and antifungal (APX2039) medications.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Anti Infective Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behaviour of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Anti Infective Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL ANTI INFECTIVE DRUGS MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Anti Infective Drugs Market Geographical Analysis (CAGR %)
  • 3.6 Global Anti Infective Drugs Market, By Drug Type (USD Billion)
  • 3.7 Global Anti Infective Drugs Market, By Indication (USD Billion)
  • 3.8 Global Anti Infective Drugs Market, By Distribution Channel (USD Billion)
  • 3.9 Future Market Opportunities
  • 3.10 Global Market Split
  • 3.11 Product Life Line

4 GLOBAL ANTI INFECTIVE DRUGS MARKET OUTLOOK

  • 4.1 Global Anti Infective Drugs Evolution
  • 4.2 Drivers
    • 4.2.1 Driver1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DRUG TYPE

  • 4.9 Overview
  • 4.10 Antibiotics
  • 4.11 Antivirals
  • 4.12 Antifungals

5 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY INDICATION

  • 5.1 Overview
  • 5.2 HIV
  • 5.3 Pneumonia
  • 5.4 Respiratory Infections
  • 5.5 Tuberculosis
  • 5.6 Others

6 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Others

7 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL ANTI INFECTIVE DRUGS MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Novartis AG
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Merck & Co., Inc
    • 9.2.1 Company Overview
    • 9.2.2 Company Insights
    • 9.2.3 Product Benchmarking
    • 9.2.4 Key Development
    • 9.2.5 Winning Imperatives
    • 9.2.6 Current Focus & Strategies
    • 9.2.7 Threat from Competition
    • 9.2.8 SWOT Analysis
  • 9.3 Alcon Pharmaceuticals Ltd
    • 9.3.1 Company Overview
    • 9.3.2 Company Insights
    • 9.3.3 Product Benchmarking
    • 9.3.4 Key Development
    • 9.3.5 Winning Imperatives
    • 9.3.6 Current Focus & Strategies
    • 9.3.7 Threat from Competition
    • 9.3.8 SWOT Analysis
  • 9.4 Quest Diagnostics Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Company Insights
    • 9.4.3 Product Benchmarking
    • 9.4.4 Key Development
    • 9.4.5 Winning Imperatives
    • 9.4.6 Current Focus & Strategies
    • 9.4.7 Threat from Competition
    • 9.4.8 SWOT Analysis
  • 9.5 AstraZeneca Plc
    • 9.5.1 Company Overview
    • 9.5.2 Company Insights
    • 9.5.3 Product Benchmarking
    • 9.5.4 Key Development
    • 9.5.5 Winning Imperatives
    • 9.5.6 Current Focus & Strategies
    • 9.5.7 Threat from Competition
    • 9.5.8 SWOT Analysis
  • 9.6 Anofi SA
    • 9.6.1 Company Overview
    • 9.6.2 Company Insights
    • 9.6.3 Product Benchmarking
    • 9.6.4 Key Development
    • 9.6.5 Winning Imperatives
    • 9.6.6 Current Focus & Strategies
    • 9.6.7 Threat from Competition
    • 9.6.8 SWOT Analysis
  • 9.7 GSK
    • 9.7.1 Company Overview
    • 9.7.2 Company Insights
    • 9.7.3 Product Benchmarking
    • 9.7.4 Key Development
    • 9.7.5 Winning Imperatives
    • 9.7.6 Current Focus & Strategies
    • 9.7.7 Threat from Competition
    • 9.7.8 SWOT Analysis
  • 9.8 Gilead Sciences
    • 9.8.1 Company Overview
    • 9.8.2 Company Insights
    • 9.8.3 Product Benchmarking
    • 9.8.4 Key Development
    • 9.8.5 Winning Imperatives
    • 9.8.6 Current Focus & Strategies
    • 9.8.7 Threat from Competition
    • 9.8.8 SWOT Analysis
  • 9.9 Novartis AG
    • 9.9.1 Company Overview
    • 9.9.2 Company Insights
    • 9.9.3 Product Benchmarking
    • 9.9.4 Key Development
    • 9.9.5 Winning Imperatives
    • 9.9.6 Current Focus & Strategies
    • 9.9.7 Threat from Competition
    • 9.9.8 SWOT Analysis
  • 9.10 Cipla
    • 9.10.1 Company Overview
    • 9.10.2 Company Insights
    • 9.10.3 Product Benchmarking
    • 9.10.4 Key Development
    • 9.10.5 Winning Imperatives
    • 9.10.6 Current Focus & Strategies
    • 9.10.7 Threat from Competition
    • 9.10.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization

LIST OF TABLES

TABLE1 Global Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 2 Global Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 3 Global Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 4 Global Anti Infective Drugs Market, By Geography, 2022 - 2030 (USD Billion)

TABLE 5 North America Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 6 North America Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 7 North America Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 8 North America Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 9 US Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE10 US Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE11 US Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE12 Canada Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE13 Canada Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE14 Canada Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE15 Mexico Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE16 Mexico Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE17 Mexico Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE18 Europe Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE19 Europe Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 20 Europe Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 21 Europe Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 22 Germany Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 23 Germany Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 24 Germany Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 25 UK Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 26 UK Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 27 UK Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 28 France Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 29 France Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 30 France Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 31 Rest of Europe Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 32 Rest of Europe Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 33 Rest of Europe Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 34 Asia-Pacific Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 35 Asia-Pacific Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 36 Asia-Pacific Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 37 Asia-Pacific Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 38 China Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 39 China Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 40 China Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 41 Japan Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 42 Japan Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 43 Japan Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 44 India Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 45 India Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 46 India Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 47 Rest of Asia-Pacific Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 48 Rest of Asia-Pacific Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 49 Rest of Asia-Pacific Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 50 RoW Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 51 RoW Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 52 RoW Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 53 RoW Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 54 Middle East and Africa Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 55 Middle East and Africa Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 56 Middle East and Africa Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 57 Latin America Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 58 Latin America Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 59 Latin America Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

  • TABLE 60 Novartis AG: Product Benchmarking
  • TABLE 61 Novartis AG: Key Development
  • TABLE 62 Merck & Co., Inc: Product Benchmarking
  • TABLE 63 Merck & Co., Inc: Key Development
  • TABLE 64 Alcon Pharmaceuticals Ltd: Product Benchmarking
  • TABLE 65 Alcon Pharmaceuticals Ltd: Key Development
  • TABLE 66 Alcon Pharmaceuticals Ltd: Product Benchmarking
  • TABLE 67 Alcon Pharmaceuticals Ltd: Key Development
  • TABLE 68 Quest Diagnostics Inc.: Product Benchmarking
  • TABLE 69 Quest Diagnostics Inc.: Key Development
  • TABLE 70 AstraZeneca Plc: Product Benchmarking
  • TABLE 71 AstraZeneca Plc: Key Development
  • TABLE 72 Anofi SA: Product Benchmarking
  • TABLE 73 Anofi SA: Key Development
  • TABLE 74 GSK: Product Benchmarking
  • TABLE 75 GSK: Key Development
  • TABLE 76 Gilead Sciences: Product Benchmarking
  • TABLE 77 Gilead Sciences: Key Development
  • TABLE 78 Novartis AG: Product Benchmarking
  • TABLE 79 Novartis AG: Key Development
  • TABLE 80 Cipla: Product Benchmarking
  • TABLE 81 Cipla: Key Development

LIST OF FIGURES

  • FIGURE1 Global Anti Infective Drugs Market Segmentation
  • FIGURE 2 Research Timelines
  • FIGURE 3 Data Triangulation
  • FIGURE 4 Market Research Flow
  • FIGURE 5 Data Sources
  • FIGURE 6 Global Anti Infective Drugs Market Overview
  • FIGURE 7 Global Anti Infective Drugs Market Geographical Analysis, 2022-2030

FIGURE 8 Global Anti Infective Drugs Market, By Drug Type (USD Million)

FIGURE 9 Global Anti Infective Drugs Market, By Indication (USD Million)

FIGURE10 Global Anti Infective Drugs Market, By Distribution Channel (USD Million)

  • FIGURE11 Future Market Opportunities
  • FIGURE12 Porters Five Force Model
  • FIGURE13 COVID-19 Analysis
  • FIGURE14 Global Anti Infective Drugs Market Geographical Analysis, 2022-2030

FIGURE15 Global Anti Infective Drugs Market, By Drug Type (USD Million)

FIGURE16 Global Anti Infective Drugs Market, By Indication (USD Million)

FIGURE17 Global Anti Infective Drugs Market, By Distribution Channel (USD Million)

  • FIGURE18 North America Snapshot
  • FIGURE19 North America Anti Infective Drugs Market Share, By Country, 2022
  • FIGURE 20 Europe Snapshot
  • FIGURE 21 Europe Anti Infective Drugs Market Share, By Country, 2022
  • FIGURE 22 Asia-Pacific Snapshot
  • FIGURE 23 Asia-Pacific Anti Infective Drugs Market Share, By Country, 2022
  • FIGURE 24 RoW Snapshot
  • FIGURE 25 RoW Anti Infective Drugs Market Share, By Country, 2022
  • FIGURE 26 Key Strategic Developments
  • FIGURE 27 Novartis AG Company Insight
  • FIGURE 28 SWOT Analysis: Novartis AG
  • FIGURE 29 Merck & Co., Inc Company Insight
  • FIGURE 30 SWOT Analysis: Merck & Co., Inc
  • FIGURE 31 Alcon Pharmaceuticals Ltd Company Insight
  • FIGURE 32 SWOT Analysis: Alcon Pharmaceuticals Ltd
  • FIGURE 33 Quest Diagnostics Inc. Company Insight
  • FIGURE 34 AstraZeneca Plc Company Insight
  • FIGURE 35 Anofi SA Company Insight
  • FIGURE 36 GSK Company Insight
  • FIGURE 37 Gilead Sciences Company Insight
  • FIGURE 38 Novartis AG Company Insight